Moderna's Stock Soars 72% in Q1, Leading Healthcare Sector
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy MRNA?
Source: Fool
- Shift in Investor Sentiment: Moderna's stock surged 72% in Q1, making it the best-performing healthcare stock in the S&P 500, reflecting a renewed investor confidence in its growth potential after a period of declining stock performance due to reduced vaccine demand.
- Diversification Strategy: The company is transitioning from a coronavirus vaccine manufacturer to a multi-faceted biotech firm, with plans to launch a flu vaccine alongside existing COVID-19 and RSV vaccines, which are expected to fund its oncology and rare disease initiatives.
- Revenue Growth Expectations: Moderna anticipates that seasonal vaccines will drive up to 10% revenue growth this year, and by cutting costs by 30% since 2024, it achieved over $2 billion in savings last year, enhancing its financial stability.
- Clinical Trial Progress: The ongoing collaboration with Merck on the mRNA-4157 project includes eight phase 2 and phase 3 trials, and successful results could significantly boost its competitive position in the oncology market, further solidifying its market presence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 51.280
Low
17.00
Averages
32.47
High
63.00
Current: 51.280
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oil Prices Surge Amid SpaceX's $2 Trillion IPO Buzz
- Oil Price Surge: Current prices for West Texas Intermediate and Brent crude have reached $110 per barrel, marking a 35% increase since December, which significantly impacts American consumers as gasoline prices rise from $2.80 to $3.80 per gallon, increasing economic strain on households.
- Futures Market Dynamics: The oil futures market is experiencing backwardation, with current month prices at $110 per barrel compared to $70 for contracts expiring in late 2026, indicating market concerns about short-term supply issues while suggesting a more optimistic long-term outlook that could influence investor strategies.
- SpaceX IPO Outlook: SpaceX has filed for a confidential IPO, potentially valued at $2 trillion, although the actual capital needed may only be $80 to $100 billion, reflecting strong market interest in the space economy and likely attracting significant investor attention.
- Economic Impact Assessment: Despite the pressure from rising oil prices, recent employment data shows a robust job market with a slight decrease in unemployment, indicating that consumers are maintaining some economic resilience in the face of rising costs, necessitating close monitoring of future economic trends.
See More
Rising Oil Prices and Space Economy Outlook
- Oil Price Surge: Current prices for West Texas Intermediate and Brent crude have reached $110 per barrel, marking a 35% increase since last December, which significantly impacts American consumers as gasoline prices rise from $2.80 to $3.80, potentially affecting the overall economy.
- Futures Market Dynamics: The oil futures market is experiencing backwardation, with current month contracts priced at $110 per barrel while contracts for late 2026 are only $70, indicating that investors believe short-term supply issues may not persist, reflecting expectations for a return to normal pricing.
- Economic Impact Assessment: Despite the pressure from rising oil prices, recent employment data shows a decrease in unemployment, suggesting that consumer confidence remains strong, which may mitigate the negative effects of higher oil prices on the economy.
- Space Economy Potential: SpaceX is seeking a confidential public listing with a potential valuation of $2 trillion; however, the actual funds needed may be significantly lower, indicating strong investor interest in the space sector and its growth prospects.
See More
Salesforce's Transformation and Challenges in the Age of AI
- Cost-Saving Strategy: Morgan DeBaun, CEO of Blavity, anticipates a shift from Salesforce's CRM platform to a more cost-efficient AI solution by early 2027, potentially saving 50% to 60%, highlighting the emphasis on cost-effectiveness in the AI era.
- Expectations for AI Features: DeBaun insists that Salesforce's AI capabilities should be included in the base offering rather than charged separately, indicating dissatisfaction with pricing strategies that could impact Salesforce's competitive position in the market.
- Market Reaction and Stock Volatility: Salesforce's stock has dropped over 35% in the past year, currently trading around $170, reflecting investor concerns about AI tools potentially disrupting traditional enterprise software, leading to a broader sell-off in software stocks.
- Future Outlook and Investment Confidence: Despite challenges, analysts remain bullish on Salesforce, with Citizens maintaining a buy rating and a $315 price target, demonstrating confidence in the company's ability to adapt to the evolving AI landscape.
See More
CDC Report Delay Raises Questions on Vaccine Efficacy
- Vaccine Efficacy Report Delayed: CDC's Jay Bhattacharya has postponed the publication of a report originally scheduled for March 19, which indicated that COVID vaccines could reduce the risk of ER visits and hospitalizations by nearly 50% in healthy adults, raising concerns about vaccine efficacy.
- Methodology Controversy: The study utilized a 'test-negative design' based on data from healthy adults receiving the 2025-2026 vaccine, showing a 50% and 55% reduction in ER visits and hospitalizations, respectively; however, Bhattacharya's concerns about the methodology may undermine public confidence in vaccines.
- Political Interference Concerns: A former CDC official suggested that the vaccine benefits are being downplayed due to the stance of HHS Secretary RFK Jr., who has pushed for restrictions on vaccine availability, potentially affecting the CDC's research publication and public health policy.
- Leadership Review Norm: An HHS spokesperson noted that it is routine for CDC leadership to review and flag concerns regarding study methodologies before publication, highlighting the complex interplay between science and politics in vaccine research dissemination.
See More
Moderna and Target Stocks Show Recovery
- Moderna Stock Surge: Since the beginning of the year, Moderna's stock has surged nearly 70%, driven by the launch of new vaccine products and a focus on seasonal vaccines, with expectations of up to 10% revenue growth this year, indicating a recovery that is attracting investor interest.
- Vaccine Revenue Support: After generating over $18 billion in vaccine revenue in 2022, Moderna is reshaping its revenue structure by introducing new COVID-19 and RSV vaccines, with seasonal vaccines expected to drive the development of other programs.
- Target's Strategic Transformation: Target's stock has risen over 20% since the start of the year, thanks to a $200 million investment plan by new CEO Michael Fiddelke aimed at improving product displays, refreshing the product assortment, and enhancing employee training to boost customer experience and sales growth.
- Competitive Advantage Enhancement: Despite pressure from competitors like Walmart, Target's lower forward P/E ratio of 14x compared to peers indicates greater growth potential, suggesting that its recovery story in the retail market is ongoing and attracting investor attention.
See More
Investors Shift Focus to Healthcare and Retail Stocks
- Market Shift: In an uncertain market, investors are turning to healthcare and retail stocks, perceived as 'safer' investments due to their potential for revenue stability, reflecting concerns over slowing economic growth.
- Moderna's Recovery: Moderna generated over $18 billion from its COVID-19 vaccine during the pandemic's early days, but its stock plummeted 90% as demand waned; however, investors are now returning, anticipating up to 10% revenue growth in 2023 as it focuses on seasonal vaccines, oncology, and rare diseases.
- Target's Transformation: Target benefited from digital initiatives during the pandemic but faced challenges afterward; new CEO Michael Fiddelke has launched a multi-year $2 billion investment plan to enhance product displays and employee training, resulting in a stock price increase of over 20% since the start of the year.
- Investment Opportunities: With increasing market interest in healthcare and retail stocks, the recovery narratives of Moderna and Target are attracting investors, particularly as Target's price-to-earnings ratio stands at just 14 times, significantly lower than its competitors, indicating substantial growth potential ahead.
See More
Oil Prices Surge Amid SpaceX's $2 Trillion IPO Buzz
- Oil Price Surge: Current prices for West Texas Intermediate and Brent crude have reached $110 per barrel, marking a 35% increase since December, which significantly impacts American consumers as gasoline prices rise from $2.80 to $3.80 per gallon, increasing economic strain on households.
- Futures Market Dynamics: The oil futures market is experiencing backwardation, with current month prices at $110 per barrel compared to $70 for contracts expiring in late 2026, indicating market concerns about short-term supply issues while suggesting a more optimistic long-term outlook that could influence investor strategies.
- SpaceX IPO Outlook: SpaceX has filed for a confidential IPO, potentially valued at $2 trillion, although the actual capital needed may only be $80 to $100 billion, reflecting strong market interest in the space economy and likely attracting significant investor attention.
- Economic Impact Assessment: Despite the pressure from rising oil prices, recent employment data shows a robust job market with a slight decrease in unemployment, indicating that consumers are maintaining some economic resilience in the face of rising costs, necessitating close monitoring of future economic trends.
See More
Rising Oil Prices and Space Economy Outlook
- Oil Price Surge: Current prices for West Texas Intermediate and Brent crude have reached $110 per barrel, marking a 35% increase since last December, which significantly impacts American consumers as gasoline prices rise from $2.80 to $3.80, potentially affecting the overall economy.
- Futures Market Dynamics: The oil futures market is experiencing backwardation, with current month contracts priced at $110 per barrel while contracts for late 2026 are only $70, indicating that investors believe short-term supply issues may not persist, reflecting expectations for a return to normal pricing.
- Economic Impact Assessment: Despite the pressure from rising oil prices, recent employment data shows a decrease in unemployment, suggesting that consumer confidence remains strong, which may mitigate the negative effects of higher oil prices on the economy.
- Space Economy Potential: SpaceX is seeking a confidential public listing with a potential valuation of $2 trillion; however, the actual funds needed may be significantly lower, indicating strong investor interest in the space sector and its growth prospects.
See More
Salesforce's Transformation and Challenges in the Age of AI
- Cost-Saving Strategy: Morgan DeBaun, CEO of Blavity, anticipates a shift from Salesforce's CRM platform to a more cost-efficient AI solution by early 2027, potentially saving 50% to 60%, highlighting the emphasis on cost-effectiveness in the AI era.
- Expectations for AI Features: DeBaun insists that Salesforce's AI capabilities should be included in the base offering rather than charged separately, indicating dissatisfaction with pricing strategies that could impact Salesforce's competitive position in the market.
- Market Reaction and Stock Volatility: Salesforce's stock has dropped over 35% in the past year, currently trading around $170, reflecting investor concerns about AI tools potentially disrupting traditional enterprise software, leading to a broader sell-off in software stocks.
- Future Outlook and Investment Confidence: Despite challenges, analysts remain bullish on Salesforce, with Citizens maintaining a buy rating and a $315 price target, demonstrating confidence in the company's ability to adapt to the evolving AI landscape.
See More
CDC Report Delay Raises Questions on Vaccine Efficacy
- Vaccine Efficacy Report Delayed: CDC's Jay Bhattacharya has postponed the publication of a report originally scheduled for March 19, which indicated that COVID vaccines could reduce the risk of ER visits and hospitalizations by nearly 50% in healthy adults, raising concerns about vaccine efficacy.
- Methodology Controversy: The study utilized a 'test-negative design' based on data from healthy adults receiving the 2025-2026 vaccine, showing a 50% and 55% reduction in ER visits and hospitalizations, respectively; however, Bhattacharya's concerns about the methodology may undermine public confidence in vaccines.
- Political Interference Concerns: A former CDC official suggested that the vaccine benefits are being downplayed due to the stance of HHS Secretary RFK Jr., who has pushed for restrictions on vaccine availability, potentially affecting the CDC's research publication and public health policy.
- Leadership Review Norm: An HHS spokesperson noted that it is routine for CDC leadership to review and flag concerns regarding study methodologies before publication, highlighting the complex interplay between science and politics in vaccine research dissemination.
See More
Moderna and Target Stocks Show Recovery
- Moderna Stock Surge: Since the beginning of the year, Moderna's stock has surged nearly 70%, driven by the launch of new vaccine products and a focus on seasonal vaccines, with expectations of up to 10% revenue growth this year, indicating a recovery that is attracting investor interest.
- Vaccine Revenue Support: After generating over $18 billion in vaccine revenue in 2022, Moderna is reshaping its revenue structure by introducing new COVID-19 and RSV vaccines, with seasonal vaccines expected to drive the development of other programs.
- Target's Strategic Transformation: Target's stock has risen over 20% since the start of the year, thanks to a $200 million investment plan by new CEO Michael Fiddelke aimed at improving product displays, refreshing the product assortment, and enhancing employee training to boost customer experience and sales growth.
- Competitive Advantage Enhancement: Despite pressure from competitors like Walmart, Target's lower forward P/E ratio of 14x compared to peers indicates greater growth potential, suggesting that its recovery story in the retail market is ongoing and attracting investor attention.
See More
Investors Shift Focus to Healthcare and Retail Stocks
- Market Shift: In an uncertain market, investors are turning to healthcare and retail stocks, perceived as 'safer' investments due to their potential for revenue stability, reflecting concerns over slowing economic growth.
- Moderna's Recovery: Moderna generated over $18 billion from its COVID-19 vaccine during the pandemic's early days, but its stock plummeted 90% as demand waned; however, investors are now returning, anticipating up to 10% revenue growth in 2023 as it focuses on seasonal vaccines, oncology, and rare diseases.
- Target's Transformation: Target benefited from digital initiatives during the pandemic but faced challenges afterward; new CEO Michael Fiddelke has launched a multi-year $2 billion investment plan to enhance product displays and employee training, resulting in a stock price increase of over 20% since the start of the year.
- Investment Opportunities: With increasing market interest in healthcare and retail stocks, the recovery narratives of Moderna and Target are attracting investors, particularly as Target's price-to-earnings ratio stands at just 14 times, significantly lower than its competitors, indicating substantial growth potential ahead.
See More
